Molecular Remission Uncoupled with Complete Haematological Response in Polycythaemia Vera Treatment with Ropeginterferon Alfa-2b

Overview

Journal Br J Haematol

Specialty Hematology

Date 2024 Oct 27

PMID 39462216

Authors

Shanshan Suo

Rong Feng Fu

Albert Qin

Zonghong Shao

Jie Bai

Hu Zhou

Na Xu

Suning Chen

Xuelan Zuo

Xin Du

Minghui Duan

Li Wang

Pei Li

Xuhan Zhang

Sujiang Zhang

Daoxiang Wu

Jingjing Zhang

Zhijian Xiao

Lei Zhang

Jie Jin

Affiliations

Soon will be listed here.

Citing Articles

The higher initial dose and accelerated titration regimen of ropeginterferon as a treatment option for certain patients with polycythaemia vera.

Qin A, Zhang L, Jin J Br J Haematol. 2025; 206(3):986-987.

PMID: 39800983 PMC: 11886929. DOI: 10.1111/bjh.19998.

References

Jin J, Zhang L, Qin A, Wu D, Shao Z, Bai J . A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera. Exp Hematol Oncol. 2023; 12(1):55. PMC: 10286412. DOI: 10.1186/s40164-023-00415-0. View

Jin J, Qin A, Zhang L, Shen W, Wang W, Zhang J . A phase II trial to assess the efficacy and safety of ropeginterferon α-2b in Chinese patients with polycythemia vera. Future Oncol. 2023; 19(11):753-761. DOI: 10.2217/fon-2022-1141. View

Qin A . Mechanism of Action of Ropeginterferon Alfa-2b in Polycythemia Vera Treatment. Clin Ther. 2024; 46(5):439-440. DOI: 10.1016/j.clinthera.2024.03.005. View

Qin A, Wu D, Li Y, Zhang J, Wang W, Shen W . Exposure-efficacy and exposure-safety analyses of ropeginterferon alfa-2b treatment in patients with polycythaemia vera. Br J Clin Pharmacol. 2024; 90(6):1493-1502. DOI: 10.1111/bcp.16043. View

Gisslinger H, Zagrijtschuk O, Buxhofer-Ausch V, Thaler J, Schloegl E, Gastl G . Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera. Blood. 2015; 126(15):1762-9. PMC: 4608390. DOI: 10.1182/blood-2015-04-637280. View

Barosi G, Birgegard G, Finazzi G, Griesshammer M, Harrison C, Hasselbalch H . Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood. 2009; 113(20):4829-33. DOI: 10.1182/blood-2008-09-176818. View

Kiladjian J, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M . Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b. Leukemia. 2022; 36(5):1408-1411. PMC: 9061291. DOI: 10.1038/s41375-022-01528-x. View

Tefferi A, Vannucchi A, Barbui T . Polycythemia vera: historical oversights, diagnostic details, and therapeutic views. Leukemia. 2021; 35(12):3339-3351. PMC: 8632660. DOI: 10.1038/s41375-021-01401-3. View

Suo S, Fu R, Qin A, Shao Z, Bai J, Chen S . Effective Management of Polycythemia Vera With Ropeginterferon Alfa-2b Treatment. J Hematol. 2024; 13(1-2):12-22. PMC: 11027776. DOI: 10.14740/jh1245. View

10.

Moliterno A, Kaizer H, Reeves B . JAK2 V617F allele burden in polycythemia vera: burden of proof. Blood. 2023; 141(16):1934-1942. PMC: 10163319. DOI: 10.1182/blood.2022017697. View

11.

Barbui T, Thiele J, Gisslinger H, Kvasnicka H, Vannucchi A, Guglielmelli P . The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J. 2018; 8(2):15. PMC: 5807384. DOI: 10.1038/s41408-018-0054-y. View

12.

Edahiro Y, Ohishi K, Gotoh A, Takenaka K, Shibayama H, Shimizu T . Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study. Int J Hematol. 2022; 116(2):215-227. DOI: 10.1007/s12185-022-03341-9. View

13.

Qin A, Urbanski R, Yu L, Ahmed T, Mascarenhas J . An alternative dosing strategy for ropeginterferon alfa-2b may help improve outcomes in myeloproliferative neoplasms: An overview of previous and ongoing studies with perspectives on the future. Front Oncol. 2023; 13:1109866. PMC: 9913265. DOI: 10.3389/fonc.2023.1109866. View

14.

Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M . Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol. 2020; 7(3):e196-e208. DOI: 10.1016/S2352-3026(19)30236-4. View